Abbvie To Acquire Immunogen, Including Its Flagship Cancer Therapy Elahere® (Mirvetuximab Soravtansine-Gynx), Expanding Solid Tumor Portfolio
Acquiring Company
AbbVie Inc.
Acquired Company
ImmunoGen
North ChicagoWalthamManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaBiotechnologyDescription
AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
Quick answer
AbbVie Inc. is acquiring ImmunoGen, announced November 30, 2023. AbbVie Inc. is based in North Chicago, Illinois, United States.
- How much did AbbVie Inc. pay for ImmunoGen?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and ImmunoGen based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. ImmunoGen is based in Waltham, Massachusetts, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Abbvie To Acquire Cerevel Therapeutics In Transformative Transaction To Strengthen Neuroscience Pipeline (December 6, 2023)
- Lilly Completes Acquisition Of Point Biopharma (December 27, 2023)
- United Therapeutics To Acquire Miromatrix Medical (October 30, 2023)
- Kodiak Gas Services, Inc. To Acquire Csi Compressco Lp In An $854 Million All-Equity Transaction, $854M (December 19, 2023)
- Certara Acquires Applied Biomath Expanding Its Biosimulation Portfolio To Industrialize New Capabilities For Optimal Dosing For Novel Therapies (December 13, 2023)
- Danaher Completes Acquisition Of Abcam (December 6, 2023)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired ImmunoGen?
ImmunoGen was acquired by AbbVie Inc., based in North Chicago. The deal was reported on November 30, 2023. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire ImmunoGen?
AbbVie Inc.'s acquisition of ImmunoGen was reported on November 30, 2023. AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does ImmunoGen do?
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. It is privately held, operating in Biotechnology, and is based in Waltham.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.